GSK recently made the decision to resume the domestic promotional activities of diabetes treatment 'Avandia'
On May 12, according to the related pharmaceutical industry, GSK recently made the decision to resume the domestic promotional activities of diabetes treatment 'Avandia' (rosiglitazone), and plans to assign personnel for marketing. However, in the case of Avandia, its patent has already expired. ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
